title: Fenofibrate improves microcirculation in patients with hyperlipidemia.
abstract: In order to investigate the effect of fenofibrate on microcirculation, 16 patients (5 female, 11 male, age 58 +/- 8 years) were studied with the aid of nailfold capillaroscopy before and after treatment with 200 mg fenofibrate per day over six weeks. Fenofibrate resulted in a significant decrease in triglycerides, total and LDL-cholesterol and apolipoprotein B and an increase in apolipoprotein A. As a parameter of an improved microcirculation the time to peak capillary blood cell velocity during postreactive hyperemia (occlusion of the lower arm for 2 minutes, 200 mmHg) decreased markedly from 45 +/- 5 to 16 +/- 3 s, p < 0.0001). Fibrinogen levels were significantly decreased (p < 0.04) in contrast to other parameters with a possible impact on microvascular perfusion (hemoglobin, hematocrit, mean platelet volume, total protein) and to blood pressure and heart rate. These findings suggest that fenofibrate treatment improves microcirculation in patients with hyperlipidemia. This beneficial effect of fenofibrate may arise from two leading mechanisms. One of these might be the decrease in fibrinogen levels reducing plasma viscosity, the other mechanism might be an indirect effect on functional abnormalities of the vascular endothelium arising from hyperlipdidemia. By lowering plasma lipids fenofibrate is likely to restore the impaired formation or efficacy of the endothelium derived relaxing factor (nitric oxide, NO).
authors.affiliation: Medical Department, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany. DSZ-Haak@em.uni-frankfurt.de
authors.forename: T
authors.initials: T
authors.lastname: Haak
authors.forename: E
authors.initials: E
authors.lastname: Haak
authors.forename: K
authors.initials: K
authors.lastname: Kusterer
authors.forename: A
authors.initials: A
authors.lastname: Weber
authors.forename: M
authors.initials: M
authors.lastname: Kohleisen
authors.forename: K H
authors.initials: KH
authors.lastname: Usadel
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D011345:Fenofibrate / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy / Q000503:physiopathology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged
chemical_list: D000960:Hypolipidemic Agents; D011345:Fenofibrate